Immix Biopharma (IMMX) awards RSUs and stock options to director Helen Adams
Rhea-AI Filing Summary
Immix Biopharma director Helen C. Adams received new equity awards as part of her compensation. She was granted 6,250 restricted stock units of common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or the company’s 2027 annual shareholder meeting, subject to her continued service.
Adams was also granted stock options for 12,500 shares of common stock at an exercise price of $8.78 per share, expiring on May 22, 2036. These options vest in substantially equal monthly installments over 12 months following the grant date, or sooner if the 2027 annual meeting occurs earlier. After the RSU grant, her direct common stock holdings total 181,004 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Adams Helen C.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 12,500 | $0.00 | -- |
| Grant/Award | Common Stock | 6,250 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 12,500 shares (Direct);
Common Stock — 181,004 shares (Direct)
Footnotes (1)
- The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer. The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date.
Key Figures
RSU grant: 6,250 RSUs
Options granted: 12,500 options
Option exercise price: $8.78 per share
+3 more
6 metrics
RSU grant
6,250 RSUs
Granted to director Helen C. Adams, vesting by 2027 annual meeting
Options granted
12,500 options
Stock options linked to common stock, granted on May 22, 2026
Option exercise price
$8.78 per share
Exercise price for 12,500 stock options
Option expiration
May 22, 2036
Expiration date of stock options granted to Adams
Common shares held
181,004 shares
Direct Immix Biopharma common stock holdings after RSU grant
Transaction code
Code A (acquisition)
Indicates grant/award acquisitions of RSUs and options
Key Terms
restricted stock units, 2021 Equity Incentive Plan, vesting, stock option, +2 more
6 terms
restricted stock units financial
"The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2021 Equity Incentive Plan financial
"granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan"
vesting financial
"RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
stock option financial
"The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"Stock Option (Right to Buy)... conversion_or_exercise_price: "8.7800""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
annual meeting of stockholders financial
"the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Helen C. Adams report at Immix Biopharma (IMMX)?
Helen C. Adams reported acquiring equity awards as compensation, including 6,250 restricted stock units and stock options for 12,500 shares. These awards were granted at no cash cost to her and are tied to future service-based vesting conditions.
What are the terms of Helen C. Adams’s new stock options in Immix Biopharma (IMMX)?
Adams received stock options for 12,500 shares of Immix Biopharma common stock with an exercise price of $8.78 per share. The options expire on May 22, 2036 and vest in substantially equal monthly installments over 12 months following the grant date.
When will Helen C. Adams’s Immix Biopharma (IMMX) RSUs vest?
Her 6,250 restricted stock units will vest in full on the earlier of the one-year anniversary of the grant date or the date of Immix Biopharma’s 2027 annual meeting of stockholders, assuming she continues to serve with the company through the applicable vesting date.
Are Helen C. Adams’s Immix Biopharma (IMMX) equity awards open-market purchases?
No. The Form 4 shows grant or award acquisitions coded as “A,” indicating compensation-related RSUs and stock options. The awards were granted under Immix Biopharma’s 2021 Equity Incentive Plan rather than being bought in the open market at prevailing share prices.